ReviewNeuro-oncology advances
New developments in neurofibromatosis type 2 and vestibular schwannoma.
Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05521048 (Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- Frailty, Surgical Time, and Surgical Complications Increase Length of Stay Following Large Vestibular Schwannoma Resection.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Neurogenetic tumor syndromes: The current landscape of workup and treatment.Neuro-oncology practice · 2026Review
- Advancements in Preclinical Models forCancers · 2026Review
- T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction.Brain communications · 2026Review
- The tumour immune microenvironment is enriched but suppressed in vestibular schwannoma compared to meningioma: therapeutic implications for NF2-related schwannomatosis.Acta neuropathologica communications · 2025Article
- NF2-associated schwannomatosis (NF2): genetics, manifestations, and emerging therapeutic approaches.Trends in molecular medicine · 2025Article
- iPSC-based merlin-deficient Schwann cell-like spheroids as anGenes & diseases · 2025Article
- Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double-Blind, Placebo-Controlled Study Proposal.Laryngoscope investigative otolaryngology · 2025Review
- Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma.Nature communications · 2025Article
- Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.Cancers · 2025Review
- Angiotensin-Receptor Blockers Prevent Vestibular Schwannoma-Associated Hearing Loss.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2025Article
- Clinical Presentation, Treatment Outcomes, and Demographic Trends in Vestibular Schwannomas: A 135-Case Retrospective Study.Journal of clinical medicine · 2025Article
- Schwann cells in the inner ear: development, disease, and regeneration.Frontiers in cellular neuroscience · 2025Review
- Papilledema in NF2-related Schwannomatosis without Ventriculomegaly and Overt Intracranial Hypertension: A Case Series and Literature Review.NMC case report journal · 2025Article
- Cochlear signal intensity changes in vestibular schwannoma: a balanced fast field-echo MRI study.Frontiers in neurology · 2025Article
- Investigating cochlear cellular dynamics in neurofibromatosis type 2-associated schwannomatosis: a histopathological study.Frontiers in neurology · 2025Article
- Neurofibromatosis type 2 misdiagnosed as amblyopia-a case report and literature review.Frontiers in medicine · 2025Article
- Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.Disease models & mechanisms · 2024Article
- Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis.Oncogene · 2024Article
- Natural history of hearing and tumor growth in vestibular schwannoma in neurofibromatosis type 2-related schwannomatosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of multiple nervous system tumors due to mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.